Expression of programmed death 1 and its ligands in the liver of autoimmune hepatitis C57BL/6 mice

Chinese Medical Journal

Volumn 122, Issue 16, 2009, Pages 1941-1946

  Cao, Jin ^a   Liu, Feng Xia ^a   Yu, Meng Xue ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Autoimmune hepatitis; Cytokine; Programmed death 1; Programmed death 1 ligands; Reverse transcription polymerase chain reaction

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 4; LYMPHOCYTE ANTIGEN; MESSENGER RNA; PROGRAMMED DEATH 1 LIGAND 1 PROTEIN; PROGRAMMED DEATH 1 LIGAND 2 PROTEIN; PROGRAMMED DEATH 1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE HEPATITIS; C57BL 6 MOUSE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; LIVER LEVEL; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; UPREGULATION;

ANIMALS; ANTIGENS, CD80; ANTIGENS, SURFACE; APOPTOSIS REGULATORY PROTEINS; HEPATITIS, AUTOIMMUNE; INTERFERON-GAMMA; INTERLEUKIN-4; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; PEPTIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349540941     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.16.019     Document Type: Article

References (37)

1. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006; 354: 54-66.
2. Czaja AJ. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev Gastroenterol Hepatol. 2007; 1: 113-128.
3. Ichiki Y, Aoki CA, Bowlus CL, Shimoda S, Ishibashi H, Gershwin ME. T cell immunity in autoimmune hepatitis. Autoimmun Rev 2005; 4: 315-321.
4. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996; 8: 765-772.
5. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002; 2: 116-126.
6. Lázár-Molnár E, Yan Q, Cao E, Ramagopal U, Nathenson SG, Almo SC. Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proc Natl Acad Sci U S A 2008; 105: 10483-10488.
7. Khoury SJ, Sayegh MH. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity 2004; 20: 529-538.
8. Oikawa T, Takahashi H, Ishikawa T, Hokari A, Otsuki N, Azuma M, et al. Intrahepatic expression of the co-stimulatory molecules programmed death-1, and its ligands in autoimmune liver disease. Pathol Int 2007; 57: 485-492.
9. Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, et al. Expression of programmed death 1ligands by murine T cells and APC. J Immunol 2002; 169: 5538-5545.
10. Eppihimer MJ, Gunn J, Freeman GJ, Greenfield EA, Chernova T, Erickson J, et al. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation 2002; 9: 133-145.
11. Nakazawa A, Dotan I, Brimnes J, Allez M, Shao L, Tsushima F, et al. The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. Gastroenterology 2004; 126: 1347-1357.
12. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2: 261-268.
13. Benda B, Ljunggren HG, Peach R, Sandberg JO, Korsgren O. Costimulatory molecules in islet xenotransplantation: CTLA-4 Ig treatment in CD40 ligand-deficient mice. Cell Transplant 2002; 11: 715-720.
14. Judge TA, Wu Z, Zheng XG, Sharpe AH, Sayegh MH, Turka LA. The role of CD80, CD86 and CTLA-4 in alloimmune responses and the induction of long-term allograft survival. J Immunol 1999; 162: 1947-1951.
15. Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, Freeman GJ, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 2003; 33: 2706-2716.
16. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006; 203: 883-895.
17. Waisman A, Yogev N. B7-H1 and CD8+ Treg: the enigmatic role of B7-H1 in peripheral tolerance. Eur J Immunol 2009; 39: 1448-1451.
18. Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 2001; 22: 265-268.
19. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141-151.
20. + T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid. J Rheumatol. 2003; 30: 1410-1419.
21. Kobayashi M, Kawano S, Hatachi S, Kurimoto C, Okazaki T, Iwai Y, et al. Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjogren's syndrome. J Rheumatol 2005; 32: 2156-2163.
22. Mataki N, Kikuchi K, Kawai T, Higashiyama M, Okada Y, Kurihara C, et al. Expression of PD-1, PD-L1, and PD-L2 in the liver in autoimmune liver diseases. Am J Gastroenterol 2007; 102: 302-312.
23. Schramm C, Protschka M, Köhler HH, Podlech J, Reddehase MJ, Schirmacher P, et al. Impairment of TGF-beta signaling in T cells increases susceptibility to experimental autoimmune hepatitis in mice. Am J Physiol Gastrointest Liver Physiol 2003; 284: G525-G535.
24. Lohse AW, Manns M, Dienes HP, Meyer zum Büschenfelde KH, Cohen IR, Cohen IR. Experimental autoimmune hepatitis: disease induction, time course and T-cell reactivity. Hepatology 1990; 11: 24-30.
25. Lohse AW, Brunner S, Kyriatsoulis A, Manns M, Meyer zum Buschenfelde KH. Autoantibodies in experimental autoimmune hepatitis. J Hepatol 1992; 14: 48-53.
26. Lohse AW, Dienes HP, Meyer zum Buschenfelde KH. Suppression of murine experimental autoimmune hepatitis by T-cell vaccination or immunosuppression. Hepatology 1998; 27: 1536-1543.
27. Jaeckel E. Animal models of autoimmune hepatitis. Semin Liver Dis. 2002; 22: 325-338.
28. Youngnak P, Kozono Y, Kozono H, Iwai H, Otsuki N, Jin H, et al. Differential binding properties of B7-H1 and B7-DC to programmed death-1. Biochem Biophys Res Commun 2003; 307: 672-677.
29. Nishikage T, Seki S, Toyabe S, Abo T, Kagata Y, Iwai T, et al. Inhibition of concanavalin A-induced hepatic injury of mice by bacterial lipopolysaccharide via the induction of IL-6 and the subsequent reduction of IL-4: the cytokine milieu of concanavalin A hepatitis. J Hepatol 1999; 31: 18-26.
30. Hussain MJ, Mustafa A, Gallati H, Mowat AP, Mieli-Vergani G, Vergani D. Cellular expression of tumour necrosis factor-alpha and interferon-gamma in the liver biopsies of children with chronic liver disease. J Hepatol 1994; 21: 816-821.
31. Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A 2003; 100: 5336-5341.
32. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.
33. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001; 291: 319-322.
34. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996; 8: 765-772.
35. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008; 224: 166-182.
36. Tiegs G, Hentschel J, Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 1992; 90: 196-203.
37. Gantner F, Leist M, Lohse AW, Germann PG, Tiegs G. Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology 1995; 21: 190-198.